©Inserm/Jammart, Baptiste, autophagy vesicle (HCV induced)
A study published in The Lancet on 11 february 2019 shows that direct-acting antivirals have short-term clinical benefits in the treatment of hepatitis C virus infection. These results come from ANRS-funded interdisciplinary research conducted by clinicians,hepatologists, and epidemiologists of the Inserm, Sorbonne University and AP-HP and coordinated by Professors Fabrice Carrat and Stanislas Pol, and Dr Hélène Fontaine, in 9895 patients of the ANRS CO 22 HEPATHER national cohort recruited in 32 centers in France.
The most recent treatments of hepatitis C virus (HCV) infection, the direct-acting antivirals (DAAs), are remarkably effective. Indeed, they eliminate the virus in almost all treated patients (95% in general) in 8 to 12 weeks. DAAs were first prescribed in France in 2014. Initially, priority was given to patients with advanced HCV infection, but from January 2017 DAA therapy was extended to all patients with chronic HCV infection.
The virologic efficacy of DAAs is well established, but until now prospective data on their clinical efficacy (ie, their impact on the progression of liver disease associated with HCV infection in real life) were scarce and related to highly selected patients or to patients from retrospective surveys. An ANRS-funded team of researchers has now compared clinical progression of HCV infection in patients receiving or not receiving DAA therapy. The researchers monitored clinical progression in “real life” in 9895 HCV-infected patients included between 2012 and 2015 in the ANRS CO22 HEPATHER cohort (see box below).
“We could have expected these results. It seems logical that the elimination of the virus causing the damage is linked to clinical improvement,” said Prof Fabrice Carrat. “Our results show that these benefits are obtained soon after virologic control and the patients are no longer highly selected as in early trials. Our analysis reflects real-world efficacy for all patients.”
The prolonged collection of data from these patients cured of an HCV infection will allow definition of the long-term benefit of DAA therapy and of the modalities needed for medical follow-up (How frequent should liver cancer screening be? How long after the cure? At what cost?). One of the difficulties sometimes encountered in this sort of study arises when patients who are cured are lost to follow-up. The “linking” of medical data from the patients of ANRS CO22 HEPATHER cohort to the national health data system (SNDS), which was validated by the French Data Protection Authority (CNIL) on 19 July 2018, should help researchers obtain exhaustive information on healthcare consumption by these patients over the long term.
(1) Fabrice Carrat (Institut Pierre Louis d’Epidémiologie et de Santé Publique, Sorbonne université, Inserm UMS-20 – unité de santé publique – hôpital Saint-Antoine, AP-HP), Stanislas Pol (Département d’Hépatologie, Hôpital Cochin AP-HP; Université Paris-Descartes; Inserm, Institut Pasteur), Hélène Fontaine (Département d’Hépatologie, Hôpital Cochin, AP-HP).
(2) Median: the value that separates the higher half from the lower half of a data sample.
(Français) L’existence de réservoirs cellulaires où se cachent des virus VIH « dormants » chez les patients infectés sous traitement est un obstacle majeur à l’éradication du virus. Dans une étude parue aujourd’hui dans la revue Nature Microbiology, une équipe de recherche de l’Institut ...
Teams from AP-HP, INRA, Gustave Roussy and Inserm can demonstrate the role of microbiota in the response of immunotherapy for cancer. They show that in man, the composition of gut microbiota can help to identify the patients who will respond favourably or ...
“Clinical outcomes in patients with chronic hepatitis C following direct-acting antiviral therapy: a prospective cohort study”
Prof. Fabrice CARRAT, PhD,1,2 Hélène FONTAINE, MD,3 Céline DORIVAL, PhD,1 Mélanie SIMONY, MS,4 Alpha DIALLO, MD,5 Prof. Christophe HEZODE, MD6 Prof. Victor DE LEDINGHEN, MD,7 Prof. Dominique LARREY, MD,8 Georges HAOUR, MSc,1 Prof. Jean-Pierre BRONOWICKI, MD,9 Prof. Fabien ZOULIM, MD,10 Prof. Tarik ASSELAH, MD,11 Prof. Patrick MARCELLIN, MD,11 Prof. Dominique THABUT, MD,12 Prof. Vincent LEROY, MD,13 Prof. Albert TRAN, MD,14 Prof. François HABERSETZER,MD,15 Prof. Didier SAMUEL, MD,16 Prof. Dominique GUYADER, MD,17 Prof. Olivier CHAZOUILLERES, MD,18 Prof. Philippe MATHURIN, MD,19 Sophie METIVIER, MD,20 Prof. Laurent ALRIC, MD,21 Ghassan RIACHI, MD,22 Jérôme GOURNAY, MD,23 Prof. Armand ABERGEL, MD,24 Prof. Paul CALES, MD,25 Prof. Nathalie GANNE, MD,26 Prof. Véronique LOUSTAUD-RATTI, MD,27 Louis D’ALTEROCHE, MD,28 Xavier CAUSSE, MD,29 Claire GEIST, MD,30 Anne MINELLO, MD,31 Isabelle ROSA, MD,32 Moana GELU-SIMEON, MD,33 Isabelle PORTAL, MD,34 Prof. François RAFFI, MD,35 Marc BOURLIERE, MD,36 Prof. Stanislas POL, MD37 for the French ANRS CO22 Hepather cohort
The Lancet Published online the 11 February http://dx.doi.org/10.1016/S0140-6736(18)32111-1